Trending...
- Phillip A. Villanueva, MD, ABNS, is being recognized by Continental Who's Who
- Beyond Visionary Has Partnered With Heal America To Host INFORM Dallas
- World's First Walkie-Talkie Bone Conduction Sport Headphones
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of an inducement award to one new employee. The Compensation Committee of the Board of Directors of Marinus approved the grant of a non-qualified stock option to purchase an aggregate of 13,800 shares of its common stock (the "Common Stock") as inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
This stock option grant has an exercise price of $7.93 per share, which is equal to the closing price of the Common Stock on April 12, 2022 (date of grant for such stock options). All of the stock options will vest and become exercisable as to 25% of the underlying shares on the one-year anniversary of the applicable employee's start date of employment, and will vest and become exercisable as to the remaining 75% of the underlying shares of Common Stock in 36 equal monthly installments thereafter on each monthly anniversary, subject to the applicable employee's continued employment with Marinus on such vesting dates. The stock option was granted as inducement material to the employee entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and is subject to the terms and conditions of the applicable award agreement covering such grant.
More on The PennZone
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. For more information visit www.marinuspharma.com.
Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may", "will", "expect", "anticipate", "estimate", "intend", "believe", and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this press release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Marinus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission.
More on The PennZone
Contacts
Sasha Damouni Ellis
Vice President, Corporate Affairs & Investor Relations
Marinus Pharmaceuticals, Inc.
484-253-6792
sdamouni@marinuspharma.com
This stock option grant has an exercise price of $7.93 per share, which is equal to the closing price of the Common Stock on April 12, 2022 (date of grant for such stock options). All of the stock options will vest and become exercisable as to 25% of the underlying shares on the one-year anniversary of the applicable employee's start date of employment, and will vest and become exercisable as to the remaining 75% of the underlying shares of Common Stock in 36 equal monthly installments thereafter on each monthly anniversary, subject to the applicable employee's continued employment with Marinus on such vesting dates. The stock option was granted as inducement material to the employee entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and is subject to the terms and conditions of the applicable award agreement covering such grant.
More on The PennZone
- Distinguished New York Trial Attorney and Author Donates Book Proceeds to NYU Cancer Research Center
- Treat Yourself Right This Summer With LA's Best Massage Therapy for Serious Pain Relief Near You!
- Governor Wolf: Pennsylvania's New, Lower Corporate Tax Rate Will Attract Businesses, Good Jobs
- Leading Hospitality Advisor Joins Whiteford in Pittsburgh
- Gospel Charting Artist Jeremiah Nedu Is On The Rise With New Single "Your Mercy"
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. For more information visit www.marinuspharma.com.
Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may", "will", "expect", "anticipate", "estimate", "intend", "believe", and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this press release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Marinus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission.
More on The PennZone
- Essential Utilities Appoints New Chief of Staff
- Peer-Reviewed Study Shows Measurable Impact on Employee Health and Productivity from Employee Assistance Program
- HWS Announces Top 10 Low Cost Vacation Spots
- World's First Walkie-Talkie Bone Conduction Sport Headphones
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Fulgent Genetics, Inc. (FLGT) on Behalf of Investors
Contacts
Sasha Damouni Ellis
Vice President, Corporate Affairs & Investor Relations
Marinus Pharmaceuticals, Inc.
484-253-6792
sdamouni@marinuspharma.com
Filed Under: Business
0 Comments
Latest on The PennZone
- Gov. Wolf: Education Funding Is an Investment in Pennsylvania's Future
- Pennsylvania: Wolf Administration: Hunger-Free Campus Initiative Helps College Students Access Free Nutritious Food Options
- 3i Solutions Announces New Leadership Brings a Customer-Focused Approach
- CHOP Helps Develop Platform to Speed Up Drug Development for Kids with Cancer
- Rite Aid Opens Online Scheduling for Flu Vaccines at All Locations
- Ecovyst Announces Upsize and Pricing of Secondary Offering of 13,000,000 Shares of Common Stock by Selling Stockholders and Repurchase of Common Stock
- CORRECTING and REPLACING Aurora Announces Second Quarter 2022 Results
- Help Wanted: Oakland-Based Children Rising Seeks Volunteers to Help Students Overcome COVID-Related Learning Loss
- E3 Forensic Platform Innovates again with Remote Cloud Collection
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Carvana Co. (CVNA) Investors
- Governor Wolf Announces More Than $8 Million in Funding to Support Business Growth, Job Creation in Six Pennsylvania Counties
- Zonit Launches the World's Best Automatic Transfer Switch for Industrial & Commercial Applications
- Bridget Rose Productions is producing the short documentary - "FORCE" RECON
- U. S. Steel Foundation Awards College Scholarships to Employees' Children
- Children's Hospital of Philadelphia Appoints New Chief of Critical Care Medicine
- Pennsylvania: Governor Wolf Announces $190 Million Available for Schools to Promote Healthier, Safer Environments
- Aramark Declares Quarterly Dividend
- Institutional Property Advisors Brokers $85.7 Million Grocery-Anchored Power Center Sale
- Sea Island Writers Retreat and chromatic black™ Host Three Virtual Writing Workshops
- US Dollar Provides Exceptional Value For Sightseeing Trips To Italy, Havana, Cuba, Delhi, Agra and Jaipur and Barcelona, Spain